As an awardee of the current Good Manufacturing Practices (cGMP) pool, ABL will support NCI in the development of novel vaccine and biological therapeutics to address a wide range of cancer indications. Specifically, ABL will utilize its expertise in providing services for: cGMP manufacturing; process development; analytical assay development; and product characterization.
Investigational vaccine and biological product development and manufacturing activities funded under this contract could range from recombinant proteins and viral vectors to peptides, DNA/RNA vaccines and virus-like particles leading to the production of novel anti-cancer vaccines and therapeutics.
"We are honored to be chosen by NCI to support its PREVENT Cancer Prevention program by applying ABL's broad array of research, development and manufacturing services,” said Jarlath Keating, president and chief executive officer, ABL. “This award allows ABL to continue in its long history of driving innovation and translation of critical new vaccines and therapies from the laboratory into the clinic."
ABL has been awarded the first manufacturing task order under this contract to support the manufacture of a cancer vaccine targeting prevention of tumors with microsatellite instability.
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91019D00025.